A novel MEK1/2 inhibitor induces G1/S cell cycle arrest in human fibrosarcoma cells

Oncology Reports

Volumn 24, Issue 2, 2010, Pages 329-333

  Matsui, Taka Aki ^a   Murata, Hiroaki ^a   Sowa, Yoshihiro ^a   Sakabe, Tomoya ^a   Koto, Kazutaka ^a   Horie, Naoyuki ^a   Tsuji, Yoshiro ^a   Sakai, Toshiyuki ^a   Kubo, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Cell cycle arrest; Fibrosarcoma; MEK inhibitor; p21WAF1 CIP1; P27KIP1

Indexed keywords

JTP 70902; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; N [3 [5 (4 BROMO 2 FLUOROPHENYLAMINO) 3 CYCLOPROPYL 8 METHYL 2,4,7,8 TETRAHYDRO 2H PYRIDO(2,3 D)PYRIMIDIN 1 YL] PHENYL]METHANESULFONAMIDE; PROPIDIUM IODIDE; PROTEIN P21; PROTEIN P27; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; TRYPAN BLUE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MAP2K1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; N-(3-(5-(4-BROMO-2-FLUOROPHENYLAMINO)-3-CYCLOPROPYL-8-METHYL-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PYRIDO(2,3-D)PYRIMIDIN-1-YL)PHENYL)METHANESULFONAMIDE; PROTEIN KINASE INHIBITOR; PYRIMIDINONE DERIVATIVE; SULFONAMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL MUTANT; CELL NUCLEUS; CELL POPULATION; CELL VIABILITY; CONTROLLED STUDY; DNA CONTENT; DOSE RESPONSE; DRUG SYNTHESIS; ENZYME PHOSPHORYLATION; FIBROSARCOMA; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; JAPAN; MOLECULAR THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL; SOFT TISSUE TUMOR; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; METABOLISM; PATHOLOGY; PHYSIOLOGY; TIME; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG EVALUATION, PRECLINICAL; FIBROSARCOMA; G1 PHASE; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; PROTEIN KINASE INHIBITORS; PYRIMIDINONES; S PHASE; SULFONAMIDES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 77954377143     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000863     Document Type: Article

References (42)

1. Singer S, Corson JM, Demetri GD, Healey EA, Marcus K and Eberlein TJ: Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. Ann Surg 221: 185-195, 1995.
2. Issels RD and Schlemmer M: Current trials and new aspects in soft tissue sarcoma of adults. Cancer Chemother Pharmacol 49: 4-8, 2002.
3. Donato DI, Paola E and Nielsen OS: The EORTC soft tissue and bone sarcoma group. European Organisation for Research and Treatment of Cancer. Eur J Cancer 38: 138-141, 2002.
4. Robinson MJ and Cobb MH: Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9: 180-186, 1997.
5. Widmann C, Gibson S, Jarpe B and Jhonson GL: Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 79: 143-180, 1999. (Pubitemid 29056951)
6. Barbacid M: Ras genes. Annu Rev Biochem 56: 779-827, 1987.
7. Nakatsu Y, Nomoto S, Oh-uchida M, Shimizu K and Sekigichi M: Structure of the activated c-raf-1 gene from human stomach cancer. Cold Spring Harbor Symp Quant Biol 51: 1001-1008, 1986.
8. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J and Kohno M: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813-822, 1999.
9. Oka H, Chatani Y, Hoshino R, Ogawa O, Kakehi Y, Terachi T, Okada Y, Kawaichi M, Kohno M and Yoshida O: Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 55: 4182-4187, 1995.
10. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr and Weber MJ: Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59: 279-284, 1999. (Pubitemid 29048852)
11. Yamaguchi T, Yoshida T, Kurachi R, Kakegawa J, Hori Y, Nanayama T, Hayakawa K, Abe H, Takagi K, Matsuzaki Y, Koyama M, Yogosawa S, Sowa Y, Yamori T, Tajima N and Sakai T: Identification of JTP-70902, a p15 (INK4b)-inductive compound, as a novel MEK1/2 inhibitor. Cancer Sci 98: 1809-1816, 2007.
12. English J, Pearson G, Wilsbacher J, Swantek J, Karandikar M, Xu S and Cobb MH: New insights into the control of MAP kinase pathways. Exp Cell Res 253: 255-270, 1999.
13. Bodart JF, Chopra A, Liang X and Duesbery N: Anthrax, MEK and cancer. Cell Cycle 1: 10-15, 2002.
14. Gupta S, Stuffrein S, Plattner R, Tencati M, Gray C, Whang YE and Stanbridge EJ: Role of phosphoinositide 3-kinase in the aggressive tumor growth of HT1080 human fibrosarcoma cells. Mol Cell Biol 21: 5846-5856, 2001.
15. Gupta S, Plattner R, Der CJ and Stanbridge EJ: Dissection of Ras-dependent signaling pathways controlling aggressive tumor growth of human fibrosarcoma cells: evidence for a potential novel pathway. Mol Cell Biol 24: 9294-9306, 2000.
16. Plattner R, Gupta S, Khosravi-Far R, Sato KY, Perucho M, Der CJ and Stanbridge EJ: Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells. Oncogene 18: 1807-1817, 1999.
17. Mauro A, Ciccarelli C, De Cesaris P, Scoglio A, Bouché M, Molinaro M, Aquino A and Zani BM: PKCalpha-mediated ERK, JNK and p38 activation regulates the myogenic program in human rhabdomyosarcoma cells. J Cell Sci 115: 3587-3599, 2002.
18. Ciccarelli C, Marampon F, Scoglio A, Mauro A, Giacinti C, De Cesaris P and Zani BM: p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells. Mol Cancer 4: 41-46, 2005.
19. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA and Gutkind JS: The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 60: 4873-4880, 2000.
20. Bais C, Santomasso B, Coso O, Arvanitakis L, Raaka EG, Gutkind JS, Asch AS, Cesarman E, Gershengorn MC and Mesri EA: G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391: 86-89, 1998.
21. Ding Y, Boguslawski EA, Berghuis BD, Young JJ, Zhang Z, Hardy K, Furge K, Kort E, Frankel AE, Hay RV, Resau JH and Duesbery NS: Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma. Mol Cancer Ther 7: 648-658, 2008.
22. Sebolt-Leopold JS: Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin Cancer Res 14: 3651-3656, 2008.
23. Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310, 2007.
24. Sebolt-Leopold JS and Herrera R: Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937-947, 2004.
25. Pagès G, Lenormand P, L'Allemain G, Chambard JC, Meloche S and Pouysségur J: Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci USA 90: 8319-8323, 1993.
26. 1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
27. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ and Reed SI: p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023, 1994.
28. 2/M arrest after DNA damage. J Biol Chem 276: 42971-42977, 2001.
29. 2/M promotes cyclin B-Cdc2 kinase activity. Mol Cell Biol 25: 3364-3387, 2005.
30. Albrecht JH, Poon RY, Ahonen CL, Rieland BM, Deng C and Crary GS: Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver. Oncogene 16: 2141-2150, 1998. (Pubitemid 28211689)
31. Coqueret O: New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 13: 65-70, 2003.
32. 3. Cancer Lett 129: 61-68, 1998.
33. Gartel AL, Serfas MS and Tyner AL: p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med 213: 138-149, 1996.
34. Abukhdeir AM and Park BH: P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med 10: E19, 2008.
35. De Cárcer G, Pérez de Castro I and Malumbres M: Targeting cell cycle kinases for cancer therapy. Curr Med Chem 14: 969-985, 2007.
36. Hoshino R, Tanimura S, Watanabe K, Kataoka T and Kohno M: Blockade of the extracellular signal-regulated kinase pathway induces marked G1 cell cycle arrest and apoptosis in tumor cells in which the pathway is constitutively activated: up-regulation of p27(Kip1). J Biol Chem 276: 2686-2692, 2001.
37. Roussel MF: The INK4 family of cell cycle inhibitors in cancer. Oncogene 18: 5311-5317, 1999.
38. Irwin MS and Kaelin WG: p53 family update: p73 and p63 develop their own identities. Cell Growth Differ 12: 337-349, 2001.
39. Marampon F, Ciccarelli C and Zani BM: Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non-muscle-derived human tumors. Mol Cancer 5: 31, 2006.
40. Wang LG, Liu XM, Fang Y, Dai W, Chiao FB, Puccio GM, Feng J, Liu D and Chiao JW: De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol 33: 375-380, 2008.
41. Jung P and Hermeking H: The c-MYC-AP4-p21 cascade. Cell Cycle 8: 982-989, 2009.
42. Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z, Kim DW, Hofmann CS, Pianetti S, Romieu-Mourez R, Freedman LP and Sonenshein GE: Repression of transcription of the p27 (Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene 20: 1688-1702, 2001.